JMP reiterates Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a market outperform rating and a $3 price target. Factive prescriptions for the week ended Dec. 23 were 7,067, of which 6,866 were new prescriptions, representing a total of 0.94% of the weekly prescriptions of quinolone antibiotics. This compares to 6,425 prescriptions in the previous week, 6,244 of which were new. Testim prescriptions for the week ended Dec. 23 were 5,380 compared with 5,084 for the previous week. Shares of the Waltham, Mass., pharmaceutical company were down 4 cents, or 1.75%, at $2.23 on volume of 390,332 shares versus the three-month running average of 515,172 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.